Théa Open Innovation
Overview
Théa Open Innovation is the strategic venture and licensing unit of Laboratoires Théa, focused on investing in and partnering with companies and research institutions to develop innovative products in ophthalmology.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Ripple Therapeutics | Dec 2020 | Series A | Lead |
| Galimedix Therapeutics | Mar 2023 | Strategic | Lead |
| Link Biologics | Sep 2023 | Strategic | Lead |
| Coave Therapeutics | Jul 2021 | Series B | Co-investor |
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is Théa Open Innovation based?
Théa Open Innovation is headquartered in Clermont-Ferrand, France.
When was Théa Open Innovation founded?
Théa Open Innovation was founded in 2019.
How many portfolio companies does Théa Open Innovation have?
Théa Open Innovation has 4 portfolio companies in Caplight's dataset.
What are some companies in Théa Open Innovation's portfolio?
Portfolio companies visible on Caplight include Ripple Therapeutics, Galimedix Therapeutics, Link Biologics, Coave Therapeutics.
What was Théa Open Innovation's most recent investment shown here?
Théa Open Innovation's most recent investment in this portfolio sample was in Link Biologics in 2023.
What sectors does Théa Open Innovation focus on?
Théa Open Innovation focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences.
What company stages does Théa Open Innovation focus on?
Stage focus information for Théa Open Innovation is not publicly available.